Figure 2
Figure 2. mAbTAFI/TM#16 specifically inhibits thrombomodulin-mediated activation of baboon TAFI (bTAFI) in plasma. Clot lysis assays, containing one-third diluted baboon plasma, were performed in the absence and presence of potato tuber carboxypeptidase inhibitor (PTCI) and mAbTAFI/TM#16. Assay conditions were as follows: control, thrombomodulin (TM), tick anticoagulant peptide (TAP), and TAP/TM. In the control (no inhibitor), an increase in clot lysis prolongation is observed when TM is present. PTCI inhibits bTAFIa activity, whereas mAbTAFI/TM#16 specifically inhibits the effect of TM on bTAFI activation, inhibiting lysis prolongation. Data are expressed as mean (±) range; n = 2.

mAbTAFI/TM#16 specifically inhibits thrombomodulin-mediated activation of baboon TAFI (bTAFI) in plasma. Clot lysis assays, containing one-third diluted baboon plasma, were performed in the absence and presence of potato tuber carboxypeptidase inhibitor (PTCI) and mAbTAFI/TM#16. Assay conditions were as follows: control, thrombomodulin (TM), tick anticoagulant peptide (TAP), and TAP/TM. In the control (no inhibitor), an increase in clot lysis prolongation is observed when TM is present. PTCI inhibits bTAFIa activity, whereas mAbTAFI/TM#16 specifically inhibits the effect of TM on bTAFI activation, inhibiting lysis prolongation. Data are expressed as mean (±) range; n = 2.

Close Modal

or Create an Account

Close Modal
Close Modal